<DOC>
	<DOCNO>NCT00304954</DOCNO>
	<brief_summary>This study examine whether anti-inflammatory medicine infliximab , sirolimus daclizumab , give participant 's current therapy , would prevent growth new blood vessel eye participant age-related macular degeneration ( AMD ) . Participants 55 year age old AMD drusen large 63um may eligible study . Vision study eye 20/20 20/400 . Participants randomly assign one three treatment - infliximab , sirolimus , daclizumab - observation . In addition , participant may treat ophthalmologist need AMD . Infliximab daclizumab give intravenously ( vein ) ; infusion give enrollment study , 2 week , monthly . Sirolimus pill take every day duration study . At 6 month , participant evaluate see whether continue treatment would beneficial . In addition treatment observation , participant undergo follow procedure : Physical examination enrollment 6 month . Photographs back eye , fluorescein angiography , indocyanine green angiography measurement retinal thickness enrollment month 1 , 3 6 . - Fluorescein angiography evaluate eye 's blood vessel . A yellow dye inject arm vein travel blood vessel eye . Pictures retina take use camera flash blue light eye . The picture show dye leak vessel retina , indicate possible blood vessel abnormality . - Indocyanine green angiography identify feeder vessel may supply abnormal blood vessel . This procedure similar fluorescein angiography , use green dye flash invisible light . - Optical coherence tomography measure retinal thickness . This test shin light eye produce cross-sectional picture retina . These measurement repeat study determine whether retinal thicken get good worse , stay . Tuberculin skin test chest x-ray enrollment 6 month . Blood test enrollment month 1 , 3 6 .</brief_summary>
	<brief_title>Infliximab , Sirolimus Daclizumab Treat Age-Related Macular Degeneration</brief_title>
	<detailed_description>There much interest possible role immune system AMD . Experimental model patient material , date , suggest role macrophage complement . This study hypothesize underlying mechanism lead choroidal neovascularization ( CNV ) similar play atherosclerosis . If case , investigator believe CNV treatment amenable new immunomodulatory agent direct specific part immune system . After therapy anti-angiogenic agent lead persistent remission CNV due AMD , participant treat one three immunomodulatory agent observe conjunction continue anti-angiogenic therapy . Thus participant continue anti-angiogenic therapy receive randomization . The investigator hypothesize combination therapy would inhibit progression CNV associate AMD . This open-label , phase II , randomize , single center clinical trial 18 study participant randomize receive one three immunomodulatory agent observed conjunction anti-angiogenic therapy .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Understand sign institutional review board ( IRB ) approve informed consent document study . 2 . Age great 55 year . 3 . In study eye , diagnosis AMD define presence drusen large 63 micron . 4 . Any antiangiogenic therapy study eye within 7 day begin immunosuppressive therapy . 5 . In study eye , participant 's study eye vision 20/20 20/400 . 6 . In study eye , presence CNV fovea determine investigator define one follow fluorescein angiographic ( FA ) feature : 1 . Early stipple hyperfluorescence flat retinal pigment epithelium ( RPE ) little mild leakage late frame fluorescein ( occult ) . 2 . Irregular elevation RPE exhibit discrete bright hyperfluorescence early transit phase angiogram . Stippled hyperfluorescence may present . Late frame may show persistent fluorescein stain leakage within sensory retinal detachment overlie area ( occult ) . 3 . Latephase leakage undetermined source leakage level RPE latephase frame angiogram source late leakage determine earlierphase frame angiogram ( occult ) . 4 . A welldemarcated area bright hyperfluorescence early phase angiogram leakage mid latephase frame obscure boundary area ( classic ) . 7 . For CNV lesion consider occult CNV classic CNV , one follow criterion must meet : 1 . A documented loss visual acuity ( 5 letter bestcorrected visual acuity measurement make use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart , double visual angle Snellen acuities available either outside referral center within participate center ( e.g. , 20/80 20/160 ) double visual angle require measurement variability Snellen acuity ) . OR 2 . Documented FA evidence 10 % increase lesion great linear dimension 3 month prior enrollment . OR 3 . Documented blood associate CNV . 8 . The great linear dimension entire lesion ( classic CNV , occult CNV feature could obscure identification classic occult CNV ) less equal 5400 micron great linear dimension retina measure treating ophthalmologist . 9 . Retinal photograph angiography sufficient quality , allow assessment macular area accord standard clinical practice , obtain . 10 . Women childbearing potential must pregnant lactating , must negative pregnancy test screening must practice adequate method birth control . Acceptable method birth control include intrauterine device ( IUD ) ; oral , dermal , implanted injected contraceptive ; tubal ligation ; barrier method spermicide . 11 . Willingness comply protocol . EXCLUSION CRITERIA : 1 . CNV , study eye , associate ocular disease pathologic myopia , ocular histoplasmosis posterior uveitis , etc . 2 . Presence geographic atrophy fovea study eye . 3 . Evidence retinal angiomatous proliferation suspect presence intraretinal hemorrhage , intraretinal leakage , adjoin serous pigment epithelial detachment ( PED ) presence connect retinal vessel . 4 . The presence chorioretinal anastomosis . 5 . Decreased vision , study eye , due retinal disease attributable CNV , nonexudative form AMD , geographic atrophy , inherit retinal dystrophy , uveitis epiretinal membrane . Participants additional ocular disease irreversibly compromise , followup , could likely compromise visual acuity ( VA ) study eye include amblyopia , anterior ischemic optic neuropathy , clinically significant diabetic macular edema , severe nonproliferative diabetic retinopathy , proliferative diabetic retinopathy . 6 . Decreased vision , study eye , due significant medium opacity corneal disease cataract , opacity preclude photography retina ; tear ( rip ) RPE ; vitelliformlike lesion outer retina ( e.g. , pattern dystrophy basal laminar drusen ) , idiopathic parafoveal telangiectasis , central serous retinopathy . 7 . Presence fibrosis , hemorrhage , pigment epithelial detachment hypofluorescent lesion obscure great 50 % CNV lesion . 8 . History systemic antiangiogenic treatment treatment CNV ( include photodynamic therapy pegaptanib sodium injection ) study eye transpupillary thermotherapy local treatment ( submacular surgery ) . Previous laser photocoagulation therapy acceptable , provided subfoveal . 9 . Participant know underlying systemic disease evidence serious potentially lethal uncontrolled active disease one extraocular organ system define effective medical regimen indicate . 10 . Participant corneal melting , necrotizing keratitis , impend vision loss . 11 . Participants history allergy to/or exposure mouse protein . 12 . Participant scleritis infectious etiology . 13 . Participant receive investigational therapy another antitumor necrosis factor ( TNF ) agent would interfere ability evaluate safety efficacy infliximab . 14 . Participant significant active infection require hospitalization . 15 . Participant multiple sclerosis . 16 . Participant severe ( class 3/4 ) congestive heart failure . 17 . Participant history cancer within past 5 year basal squamous cell carcinoma . 18 . Participant pregnant lactating . 19 . Participant posterior scleritis . 20 . Participant evidence liver disease ( etiology ) . History moderate severe abnormal liver function , unless document evidence normal liver enzymes provide . 21 . Participant positive PPD ( tuberculosis test ) unless clear Internal Medicine . 22 . Participant positive Chest Xray show acute pulmonary disease . 23 . Participant unexplained hematuria . 24 . Participant history alkylating therapy use . 25 . Current exam evidence ocular toxoplasmosis ; pseudoexfoliation ; external ocular infection , include conjunctivitis ; chalazion ; significant blepharitis ; aphakia study eye ( pseudophakic participant eligible ) . 26 . Intraocular surgery ( include lens replacement surgery ) within 6 week prior randomization . 27 . Recent history ( within last 6 month ) , current acute ocular periocular infection ( include history ocular herpes zoster simplex ) . 28 . Known hypersensitivity/allergy verteporfin , porfimer sodium , porphyrin , porphyria porphyrin sensitivity , hypersensitivity sunlight bright artificial light . Participation clinical study receiving , receive experimental systemic treatment AMD ( e.g. , retinoic acid , thalidomide ) . Local therapy AMD permit . 29 . Medical problem make consistent followup treatment period unlikely ( e.g. , stroke , severe myocardial infarction ( MI ) , end stage malignancy ) , contraindication perform necessary diagnostic study ( i.e. , know allergy fluorescein dye etc . ) , general poor medical risk systemic disease active uncontrolled infection . 30 . Participant history moderate severe abnormal liver function , unless document evidence normal liver enzymes provide . 31 . Participant history active pulmonary tuberculosis . 32 . Participant history active viral hepatitis . 33 . Participant chronic continue Ketoconazole use .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>92 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Remicade</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>AMD</keyword>
	<keyword>Ocular Inflammation</keyword>
</DOC>